Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Cedric G, Francois"'
Autor:
Raymond S M, Wong, Humphrey W H, Pullon, Ismail, Amine, Andrija, Bogdanovic, Pascal, Deschatelets, Cedric G, Francois, Kalina, Ignatova, Surapol, Issaragrisil, Pimjai, Niparuck, Tontanai, Numbenjapon, Eloy, Roman, Jameela, Sathar, Raymond, Xu, Mohammed, Al-Adhami, Lisa, Tan, Eric, Tse, Federico V, Grossi
Publikováno v:
Annals of Hematology. 101:1971-1986
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by complement-mediated hemolysis. C5 inhibitors (eculizumab/ravulizumab) control intravascular hemolysis but do not prevent residual extravascular hemoly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3bf846b1cc5dce676c8a819f23bd2e2
https://doi.org/10.1007/s00277-022-04903-x
https://doi.org/10.1007/s00277-022-04903-x
Autor:
David S. Boyer, Cedric G. Francois, Felix Grassmann, Delphine El Mehdi, Bernhard H. F. Weber, Philip J. Rosenfeld, Ramiro Ribeiro, Jason S. Slakter, Robert Y. Kim, Carol Chung, David Liao, Jeffrey S. Heier, Prema Abraham, David M. Brown, Charles C. Wykoff, Federico Grossi, Monica Gerber, Mohamed Hamdani, Lawrence J. Singerman, Pascal Deschatelets, Peter Nuernberg
Publikováno v:
Ophthalmology. 127:186-195
Objective Geographic atrophy (GA), a late stage of age-related macular degeneration, is a major cause of irreversible blindness. Even while central visual acuity remains relatively well preserved, GA often causes considerable compromise of visual fun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::641ac4b6cc099d8a06241f34a6589cae
https://doi.org/10.1016/j.ophtha.2019.07.011
https://doi.org/10.1016/j.ophtha.2019.07.011
Autor:
Pascal Deschatelets, Carlos M. de Castro, Hisakazu Nishimori, Britta Höchsmann, Morag Griffin, Antonio M. Risitano, Ilene C. Weitz, Kensuke Usuki, Alexander Röth, Régis Peffault de La Tour, Mohamed Hamdani, Temitayo Ajayi, Peter Hillmen, Cedric G. Francois, Lisa Tan, Jens Panse, Federico Grossi, Jean-Jacques Kiladjian, Jeff Szer
Publikováno v:
The New England journal of medicine. 384(11)
Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease characterized by chronic complement-mediated hemolysis. C5 inhibition controls intravascular hemolysis in untreated PNH but cannot address extravascular hemolysis. Pegce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7df883fd386d00ff51c01fab70727eb9
https://pubmed.ncbi.nlm.nih.gov/34706184
https://pubmed.ncbi.nlm.nih.gov/34706184
Autor:
Mohammed Al-Adhami, Pascal Deschatelets, Carlos M. de Castro, Régis Peffault de Latour, Britta Höchsmann, Morag Griffin, Alexander Röth, Kensuke Usuki, Antonio M. Risitano, Ilene C. Weitz, Lisa Tan, Cedric G. Francois, Hisakazu Nishimori, Federico Grossi, Jean-Jacques Kiladjian, Jens Panse, Peter Hillmen, Jeff Szer
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S341-S342
Context: Pegcetacoplan (PEG) is a C3 complement inhibitor recently approved by the FDA for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). PEG was superior to eculizumab (ECU; C5-inhibitor) in improving hemoglobin levels at week 16 during
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e1e57387aaa905a3787e583c6f355c0
https://doi.org/10.1016/s2152-2650(21)01795-x
https://doi.org/10.1016/s2152-2650(21)01795-x
Autor:
Carl Di Casoli, Cedric G. Francois, Federico Grossi, Robert A. Brodsky, Ilene C. Weitz, Eloy Roman, Delphine El Mehdi, Vivek R. Sharma, Jaroslaw P. Maciejewski, Lisa Tan, Pascal Deschatelets, Carlos M. de Castro
Publikováno v:
American Journal of Hematology
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, life‐threatening hematologic disease characterized by chronic complement‐mediated hemolysis and thrombosis. Despite treatment with eculizumab, a C5 inhibitor, 72% of individuals remain ane
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b4649fcc8e43f511d54cac81d337cef
https://pubmed.ncbi.nlm.nih.gov/33464651
https://pubmed.ncbi.nlm.nih.gov/33464651
Autor:
Paulo Alvarenga, Juan Ramón Benito Navarro, Cedric G. Francois, Temitayo Ajayi, David Gómez-Almaguer, Mohammed Al-Adhami, Pascal Deschatelets, Teresita Dumagay, Narcisa Sonia Cornejo Comia, Yeow Tee Goh, Raymond S.M. Wong, Daolada Kongkabpan, Henry Idrobo, Federico Grossi
Publikováno v:
Blood. 138:606-606
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening disease characterized by hemolysis and thrombosis. Many patients with PNH use C5-inhibitors (i.e., eculizumab/ravulizumab) to control their symptoms. Although C5-inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec95e3df63bf78ddf8ed4228de79eaee
https://doi.org/10.1182/blood-2021-147493
https://doi.org/10.1182/blood-2021-147493
Autor:
Federico Grossi, Pascal Deschatelets, Cedric G. Francois, Tontanai Numbenjapon, Andrija Bogdanovic, Ismail Amine, Lisa Tan, Raymond S.M. Wong, Kalina Ignatova, Jameela Sathar, Eloy Roman, Surapol Issaragrisil, Pimjai Niparuck, Eric Tse, Carl Di Casoli, Humphrey Pullon
Publikováno v:
Blood. 136:3-4
INTRODUCTION Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, clonal hematopoietic stem cell disorder characterized by chronic complement-mediated intravascular and extravascular hemolysis (IVH and EVH), and thrombosis. C5 inhibitors reduce IVH b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56d114e99dd8591e2fdcd179bb3b15fe
https://doi.org/10.1182/blood-2020-134436
https://doi.org/10.1182/blood-2020-134436
Autor:
Antonio M. Risitano, Hisakazu Nishimori, Jeff Szer, Mohamed Hamdani, C. Decastro, Alexander Röth, Jens Panse, R.P. Latour, Peter Hillmen, Kensuke Usuki, Britta Höchsmann, Morag Griffin, H. Weitz, Federico Grossi, Pascal Deschatelets, Jean-Jacques Kiladjian, L. Tan, Cedric G. Francois
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 42, Iss, Pp 12-13 (2020)
BACKGROUND In paroxysmal nocturnal hemoglobinuria (PNH), intravascular hemolysis (IVH) is mediated by the membrane attack complex, while extravascular hemolysis (EVH) is facilitated by C3 opsonization. Although eculizumab (ECU), a C5 inhibitor, inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fded6b07b905422d90f4e55917eb39b
http://www.sciencedirect.com/science/article/pii/S2531137920303072
http://www.sciencedirect.com/science/article/pii/S2531137920303072
Autor:
Alexander Röth, Antonio M. Risitano, Ilene C. Weitz, Federico Grossi, Jean-Jacques Kiladjian, Lisa Tan, Carlos M. de Castro, Britta Höchsmann, Jens Panse, Mohamed Hamdani, Peter Hillmen, Morag Griffin, Pascal Deschatelets, Jeff Szer, Hisakazu Nishimori, Kensuke Usuki, Cedric G. Francois, Régis Peffault de Latour
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S216-S217
Context Anemia persists in up to 72% of patients with paroxysmal nocturnal hemoglobinuria (PNH) despite the inhibition of C5 with eculizumab. Pegcetacoplan, a C3 inhibitor, has the potential to control both intravascular (IVH) and extravascular hemol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9dd1628b0c7ffff3863f52735ff5c623
https://doi.org/10.1016/s2152-2650(20)30783-7
https://doi.org/10.1016/s2152-2650(20)30783-7
Autor:
Cedric G. Francois, Dave Singh, Lisa Tan, Thomas Southworth, Federico Gross, Delphine El Mehdi, Carolina Vega, Helen Richardson, Pascal Deschatelets, Caroline Pattwell
Publikováno v:
Airway Cell Biology and Immunopathology.
Background: Complement proteins C3a and C5a are chemoattractants for neutrophils and macrophages, and may increase these cells in COPD lungs. Previous studies have shown that C5a is higher in COPD patients compared to controls and negatively correlat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de74ffc3eda7ceecf3da0baa9c1d57aa
https://doi.org/10.1183/1393003.congress-2017.pa1002
https://doi.org/10.1183/1393003.congress-2017.pa1002